Sanz L - Search Results

1

Tumor cell surface display of immunoglobulin heavy chain Fc by gene transfer as a means to mimic antibody therapy.

Riddle DS, Sanz L, Chong H, Thompson J, Vile RG. Riddle DS, et al. Among authors: sanz l. Hum Gene Ther. 2005 Jul;16(7):830-44. doi: 10.1089/hum.2005.16.830. Hum Gene Ther. 2005. PMID: 16000065

2

Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices.

Sanz L, Kristensen P, Blanco B, Facteau S, Russell SJ, Winter G, Alvarez-Vallina L. Sanz L, et al. Gene Ther. 2002 Aug;9(15):1049-53. doi: 10.1038/sj.gt.3301725. Gene Ther. 2002. PMID: 12101437

3

Antibody engineering, virus retargeting and cellular immunotherapy: one ring to rule them all?

Sanz L, Qiao J, Vile RG, Alvarez-Vallina L. Sanz L, et al. Curr Gene Ther. 2005 Feb;5(1):63-70. doi: 10.2174/1566523052997479. Curr Gene Ther. 2005. PMID: 15638711 Review.

4

Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy.

Thanarajasingam U, Sanz L, Diaz R, Qiao J, Sanchez-Perez L, Kottke T, Thompson J, Chester J, Vile RG. Thanarajasingam U, et al. Among authors: sanz l. Cancer Res. 2007 Jan 1;67(1):300-8. doi: 10.1158/0008-5472.CAN-06-1017. Cancer Res. 2007. PMID: 17210711 Free article.

5

Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes.

Compte M, Blanco B, Serrano F, Cuesta AM, Sanz L, Bernad A, Holliger P, Alvarez-Vallina L. Compte M, et al. Among authors: sanz l. Cancer Gene Ther. 2007 Apr;14(4):380-8. doi: 10.1038/sj.cgt.7701021. Epub 2007 Jan 12. Cancer Gene Ther. 2007. PMID: 17218946

6

Factory neovessels: engineered human blood vessels secreting therapeutic proteins as a new drug delivery system.

Compte M, Alonso-Camino V, Santos-Valle P, Cuesta AM, Sánchez-Martín D, López MR, Vicario JL, Salas C, Sanz L, Alvarez-Vallina L. Compte M, et al. Among authors: sanz l. Gene Ther. 2010 Jun;17(6):745-51. doi: 10.1038/gt.2010.33. Epub 2010 Mar 25. Gene Ther. 2010. PMID: 20336155

7

Antibody gene therapy: getting closer to clinical application?

Guijarro-Muñoz I, Compte M, Alvarez-Vallina L, Sanz L. Guijarro-Muñoz I, et al. Among authors: sanz l. Curr Gene Ther. 2013 Aug;13(4):282-90. doi: 10.2174/15665232113139990025. Curr Gene Ther. 2013. PMID: 23773178 Review.

8

Antibodies and gene therapy: teaching old 'magic bullets' new tricks.

Sanz L, Blanco B, Alvarez-Vallina L. Sanz L, et al. Trends Immunol. 2004 Feb;25(2):85-91. doi: 10.1016/j.it.2003.12.001. Trends Immunol. 2004. PMID: 15102367 Review.

9

Lymphocyte display: a novel antibody selection platform based on T cell activation.

Alonso-Camino V, Sánchez-Martín D, Compte M, Sanz L, Alvarez-Vallina L. Alonso-Camino V, et al. Among authors: sanz l. PLoS One. 2009 Sep 24;4(9):e7174. doi: 10.1371/journal.pone.0007174. PLoS One. 2009. PMID: 19777065 Free PMC article.

10

Non-hematopoietic stem cells as factories for in vivo therapeutic protein production.

Sanz L, Compte M, Guijarro-Muñoz I, Álvarez-Vallina L. Sanz L, et al. Gene Ther. 2012 Jan;19(1):1-7. doi: 10.1038/gt.2011.68. Epub 2011 May 12. Gene Ther. 2012. PMID: 21562594 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

533 results

Search Page

Filters